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Summary
Background: Tissue engineering and regenerative medicine are two rapidly advancing ﬁelds of research offering potential for effective treat-
ment of cartilage lesions. Today, chondrocytes are the cell type of choice for use in cartilage repair approaches such as autologous chondro-
cyte implantation. To verify the safety and efﬁcacy of such approaches it is necessary to determine the fate of these transplanted cells. One
way of doing this is prelabelling cells before implantation and tracking them using imaging techniques. The use of superparamagnetic iron
oxide (SPIO) for tracking of cells with magnetic resonance imaging (MRI) is ideal for this purpose. It is non-radioactive, does not require viral
transfection and is already approved for clinical use as a contrast agent.
Objective: The purpose of this study was to assess the effect of SPIO labelling on adult human chondrocyte behaviour.
Methods: Cells were culture expanded and dedifferentiated for two passages and then labelled with SPIO. Effect on cell proliferation was
tested. Furthermore, cells were cultured for 21 days in alginate beads in redifferentiation medium. Following this period, cells were analysed
for expression of cartilage-related genes, proteoglycan production and collagen protein expression.
Results: SPIO labelling did not signiﬁcantly affect any of these parameters relative to unlabelled controls. We also demonstrated SPIO reten-
tion within the cells for the full duration of the experiment.
Conclusions: This paper demonstrates for the ﬁrst time the effects of SPIO labelling on chondrocyte behaviour, illustrating its potential for
in vivo tracking of implanted chondrocytes.
ª 2008 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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Introduction
In recent years, implantation of marrow derived stromal
cells (MSCs) and chondrocytes into joints for the treatment
of cartilage-related disorders has become increasingly com-
mon. Given the risks involved in cell based therapies, much
research is currently focused on tracking of cells following
implantation. This ability to track cells following implantation
is not the only consideration to be taken into account when
choosing imaging methods. It is also important to be able to
visualise the defect and surrounding tissue to assess repair
longitudinally. For both of these purposes magnetic reso-
nance imaging (MRI) is at the fore of clinical potential.
The use of superparamagnetic iron oxide (SPIO) particles
for this purpose has proved promising in recent years. In
this approach, small particles of iron oxide are introduced
into cells and can be visualised as a hypointense signalaTel: 31-645-453980.
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961by MRI both in vitro and in vivo. While the general con-
sensus is that there are no major effects of labelling on
MSCs, some minor differences in chondrogenic and osteo-
genic differentiation have been observed6,9,10. Interestingly,
no research has been reported on the effects of SPIO label-
ling on the redifferentiation capacity of dedifferentiated
chondrocytes following in vitro expansion. The purpose of
this research was to determine the efﬁcacy and effect of
labelling in vitro expanded chondrocytes on cell viability,
proliferation and redifferentiation capacity.Materials and methodsCELL CULTUREChondrocytes were harvested from full-thickness articular cartilage from
knees of humans undergoing knee replacement surgery by digestion in pro-
nase (2 mg/ml, Sigma, St. Louis, MO, USA) for 2 h followed by overnight col-
lagenase B (1.5 mg/ml, Roche Diagnostics). Chondrocytes were
subsequently seeded at a density of 7500 cells/cm2 in T175s and cultured
for two passages, prior to labelling.CELL LABELLINGCells were labelled with Endorem (Guerbet S.A., Paris, France) and Lip-
ofectamine 2000 (Invitrogen, Breda, The Netherlands) as previously de-
scribed11. Brieﬂy, 20 ml of both Endorem and Lipofectamine were mixed
962 E. Farrell et al.: Cell labelling with superparamagnetic iron oxideseparately with 500 ml of Opti-MEM (Invitrogen). They were then combined
and left for 20 min. The culture medium was replaced by Opti-MEM and
3.25, 9.7, 29.3, 87.9 or 263.7 ml (equivalent to 2, 6.25, 18.75, 56.25, or
168.75 mg iron content) of the SPIOeLipofectamine suspension was added
drop-wise totalling 1 ml of suspension per well of a six-well plate containing
200,000 cells per well. Subsequently, the cells were incubated at 37C/
5%CO2 for 24 h and then rinsed in Phosphate Buffered Saline (PBS). Four
conditions, Control, Labelled, SPIO alone and Lipofectamine alone were
used and were subsequently cultured under the same conditions.Fig. 1. Chondrocytes are labelled overnight by SPIOeLipofectamine. Eff
Alamar Blue cytotoxicity assay. Metabolic activity of cells is expressed as a
on cell viability until the highest dose of 168 mg of SPIO per well. This de
samples were tested for four donors (two-way ANOVA *P< 0.05, ***P< 0
tive labelling of chondrocytes at a dALAMAR BLUE ASSAYThe Alamar Blue assay (Invitrogen) was used as a measure of cell viabil-
ity according to the manufacturer’s instructions. Brieﬂy, 70,000 cells were
added per well of a 12 well plate and left overnight. They were then labelled
overnight according to the above protocol. This was followed by two PBS
washes and medium was added for 4 h. After this period Alamar Blue was
added at a 1:10 concentration to the medium present. 4 h later 100 ml of
this medium-Alamar mix was placed in a 96 well plate, read at 570 and
600 nm and analysed according to the provided calculations.ects of varying concentrations of SPIO labelling was assessed by
percentage of unlabelled control cells. SPIO labelling had no effect
trimental effect was likely caused by the Lipofectamine. Duplicate
.001 signiﬁcantly different from control). Figure 1(b) illustrates effec-
ose of 18 mg of iron per well.
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nate (Keltone LV) in 0.9% NaCl (Sigma) at a concentration of
4 106 cells/ml, and beads were made as described previously12. Trans-
ferred to six-well plates (Corning BV, Schiphol-Rijk, The Netherlands), beads
were cultured in 75 ml/bead serum-free chondrogenic induction medium con-
taining Dulbecco’s modiﬁed Eagle’s medium (DMEM) supplemented with
transforming growth factor (TGF)-b2 10 ng/ml (R&D Systems, UK), IGF-1
10 ng/ml (Sigma, Missouri, USA), L-ascorbic acid 2-phosphate 25 mg/ml
(Sigma), and Insulin transferrin and selinium (ITSþ) (diluted 1:100; BD Bio-
sciences, Bedford, MA), 50 mg/ml gentamycin and 1.5 mg/ml fungizone and
cultured for 21 days. On day 21 beads were harvested for RNA extraction,
Glycosaminoglycan (GAG) and DNA assays and for histology.BIOCHEMICAL ASSAYSAlginate beads were digested overnight at 56C in papain buffer (200 mg/ml
papain in 50 mM Ethylene Diamintetraacetate (EDTA) and 5 mM L-cystein).
GAG amount in the digest was quantiﬁed using dimethylmethylene blue (DMB)
assay13. Interference from alginate in the assay was prevented by performing
the test at pH 1.5 as has been described previously14. Quantiﬁcation of sulfated
glycosaminoglycans in chondrocyte/alginate cultures, by use of 1,9-DMB. The
amount of GAG was monitored by spectrophotometer, using the ratio A530:A590
with chondroitin sulfate C (Sigma) as a standard. The amount of DNA was deter-
mined using ethidium bromide with calf thymus DNA (Sigma) as a standard.IMMUNOCYTOCHEMISTRY FOR COLLAGEN TYPE IITo prepare cytospins, three alginate beads cultured for 21 days were dis-
solved in 55 mMsodium citrate acid. After ﬁxation in cold acetone, the cytospins
were incubated with a monoclonal antibody against type II collagen (1:100,
II-II6B3; Developmental Studies Hybridoma Bank) at room temperature for
1 h.Thiswas followedby incubationwith linkand label from the link-label kit (Bio-
Genex, San Ramon, CA, USA) each for 30 min. Freshly prepared neo-fuchsin
substratewasused toachieve staining. Thenumber of cells positive for collagen
type II per 100 cells was scored in four ﬁelds of sight per specimen.Fig. 2. SPIO is retained intracellularly for 21 days in alginate. Following
redifferentiation medium, beads were dissolved and prepared as cytospin
ence of iron particles in discrete intracellular clusters as evidenced by Pr
served in the SPIO only condition. Although this was not quantiﬁed, thereGENE EXPRESSION ANALYSESPrimer and probe oligonucleotide sequences for Glyceraldehyde 3-
phosphate dehydrogenase (GAPDH), COL X, SOX 9, COL II, and Aggrecan
(AGC) assays are published by Mandl et al.15, Uitterlinden et al.16 and de Mos
et al.17, respectively. All Taqman assays were performed using triplicate
biological samples per donor using TaqmanUniversal Polymerase chain reac-
tion (PCR)MasterMix (AppliedBiosystems, #4324020) as described previously.PREPARATION OF BONE PLUGS FOR MRIEight millimeter bovine osteochondral plugs were prepared and a 4 mm
chondral defect was punched from the centre of each one. Into these defects
cells prepared in alginate gel were added. Gels contained 1000, 10,000 or
100,000 labelled cells or 10,000 unlabelled cells as a control. MR imaging
was performed on a clinical 3.0-T MRI scanner (General Electric Medical Sys-
tems, Milwaukee, WI, USA) with the standard imaging gradient set and special-
ized signal reception coils for high resolution scanning. For in vitro samples,
a custom-designed 1.0-cm-diameter surface coil (Flick Engineering Solutions
B.V, Winterswijk, The Netherlands) was used for signal reception. After im-
age-localisation scans, a three-dimensional (3-D) rf-spoiled gradient recalled
(SPGR) sequence was selected with the imaging volume positioned parallel
to the bottom of the well containing the bone plugs. Imaging parameters were
as follows: repetition time (TR)¼ 48 ms, echo time (TE)¼ 5.0 ms, ﬂip
angle¼ 8, read-out bandwidth¼ 8.1 kHz, ﬁeld-of-view (FOV)¼ 1.7 1.7 cm2,
matrix size¼ 192 160, numberof excitations (NEX)¼ 1.0, scan time¼ 11 min
30 s. Section thickness was set to 100 mm and 86 slices encoded sections.
These parameters yielded a voxel size of 88 106 100 mm3.DATA ANALYSISRelative gene expression among experimental groups was analysed by
one-way ANOVA. A P-value <0.05 was considered to indicate statistically
signiﬁcant difference. Cells were cultured from four patients separately and
carried out in triplicate for all genes analysed. Results for GAG, DNA and
number of collagen II positive cells were also analysed by one-way ANOVA
from four donors.21 days culture in alginate beads in the presence of chondrogenic
s for histological staining for iron. Figure 2 demonstrates the pres-
ussian blue staining for iron. Some iron positive cells were also ob-
were much fewer positive cells compared to the labelled condition.
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VIABILITYLabelling of chondrocytes at a range of doses had no
effect on cell viability as assessed by an Alamar Blue
cytotoxicity assay until a slight effect was observed at
a dose of 54 mg SPIO per well in the combined SPIO/
Lipofectamine condition and in the Lipofectamine only
condition at 168 mg [Fig. 1(a)]. This was likely due to
the large amount of Lipofectamine present which is
known to be cytotoxic at high doses18. Based on previ-
ous experiments to assess labelling efﬁciency and these
ﬁndings, a dose of 18 mg SPIO per well was used for
subsequent experiments. Labelling overnight at this
concentration led to a very high labelling efﬁciency as
can be seen in the Prussian blue staining [Fig. 1(b)].
There was negligible iron uptake in the SPIO only
condition.Fig. 3. SPIO labelling does not affect expression levels of common chond
performed with triplicate samples for each of four donors. Gene express
were not signiﬁcantly different between the labelled condition and unlab
n¼ 4). All genes expression levels are relative to GAPDH expression.
days in culture. As can be seen in Fig. 3, GAG production per DNA wa
were also not signiﬁcantly differeLABELLED CHONDROCYTES RETAIN SPIO FOR UP TO
3 WEEKS IN ALGINATETo demonstrate the retention of iron particles after 21
days in alginate beads, Prussian blue staining was carried
out. In unlabelled controls, no positive staining was ob-
served [Fig. 2(a)]. In the labelled condition, iron particles
were retained intracellularly for 3 weeks in alginate beads
[Fig. 2(b)]. Interestingly, some cells cultured with SPIO
alone and no transfection agent also contained iron
[Fig. 2(c)]. This was much fewer cells than in the labelled
condition, though the pattern of staining was similar. In
both SPIO containing conditions iron seemed to be located
in discrete intracellular organelles/vacuoles.REALTIME QUANTITATIVE RT-PCR AND GAG/DNA ANALYSIS
OF CHONDROCYTE REDIFFERENTIATIONTo assess chondrocyte redifferentiation mRNA expres-
sion levels of four chondrogenic markers were assessedrogenic genes or GAG production. Realtime RT-PCR analysis was
ion levels of collagen type II, Sox 9, collagen type X and aggrecan
elled controls or either of the labelling controls (one-way ANOVA,
Total DNA per bead and GAG per bead were assayed after 21
s not signiﬁcantly altered by iron oxide labelling. Total DNA levels
nt from unlabelled controls.
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nate with chondrogenic redifferentiation medium. For all
four genes analyses, collagen type II, Sox 9, collagen
type X and aggrecan, no signiﬁcant difference was ob-
served between control samples and any treatment condi-
tion. While a trend towards lower gene expression was
observed in the Lipofectamine condition, this did not reach
statistical signiﬁcance (n¼ 4, P¼ 0.6187, 0.2574, 0.4672
and 0.7217, respectively for the four genes Fig. 3). There
was no effect of any of the treatment conditions on the
amounts of DNA present in the alginate beads (n¼ 4,
P¼ 0.9145, data not shown). GAG production was also
not signiﬁcantly affected by cell labelling (n¼ 4,
P¼ 0.581), though a slight decrease in GAG production
was observed in both the labelled and Lipofectamine con-
ditions indicating a possible effect of Lipofectamine on cell
behaviour.COLLAGEN TYPE II PROTEIN EXPRESSIONAs collagen type II protein expression is the deﬁnitive
indicator of the chondrogenic phenotype, immunocyto-
chemistry was performed (Fig. 4). While there was some
inter donor variation in the amount of positive cells, there
was no signiﬁcant difference between any of the conditions
(n¼ 4, P¼ 0.9491).TRACKABILITY OF LABELLED CELLS IN A CARTILAGE DEFECTAs a proof of principle different concentrations of
labelled cells were placed in an ex vivo cartilage defect
model to determine the ability to track cells and differ-
entiate from surrounding cartilage (Fig. 5). At 1000
labelled cells in a 4 mm defect no cells were detectable
above background. However, at a concentration of
10,000 and 100,000 cells hypointense signals were ob-
served in the defect clearly distinct from the surround-
ing cartilage. No signal was observed from 10,000
unlabelled cells.Fig. 4. Collagen type II production is unaffected by SPIO labelling in algi
ferentiated chondrocytes, collagen type II immunocyochemistry was carr
with no signiﬁcant difference in the number of positive cells when labelled
lagen staining between conditions are simply as a result of cellular distrib
difference in relative numbDiscussion
This paper for the ﬁrst time examines the effects of SPIO
labelling on human chondrocyte behaviour/performance,
a vital aspect to treatment of cartilage damage by the Auto-
logous chondrocyte implantation (ACI) technique. To assess
the effects of SPIO labelling on redifferentiation capacity of
chondrocytes, a standard alginate bead experiment was
performed. Chondrocytes were cultured in 3-D in the pres-
ence of TGF b for 21 days. Redifferentiation was conﬁrmed
by the expression of cartilage speciﬁc genes, proteoglycan
production and collagen type II protein expression. None
of these criteria were signiﬁcantly altered by transfection of
the cells with SPIO particles or SPIO or transfection agent
alone. Throughout the culture period, SPIO was retained
intracellularly as evidenced by Prussian blue staining.
The ability to safely track implanted cells is extremely im-
portant in cell therapies both to exclude migration of cells
from the implantation site and to potentially monitor long-
term cell survival. The use of SPIO for this purpose is there-
fore ideal3. SPIO labelled cells can be tracked for up to 7
weeks post labelling10 and have been shown in several re-
cent studies to have no or only minor effects on cell viability
and differentiation capacity in vitro. The effects of label on
implanted cells will have to be investigated further. The
added beneﬁt of using SPIO is that MRI techniques for vis-
ualisation of cartilage lesions are vastly improved enabling
clinicians to monitor the repair of a defect long after the label
has been metabolised19.
The use of Lipofectamine as transfection agent is not
ideal as it is currently not approved for clinical use. Interest-
ingly, some iron was present in cells cultured with SPIO
alone and appeared to be localised in a similar pattern to
the labelled condition. This effect could potentially lead to
the labelling of chondrocytes without a transfection agent.
This has recently been demonstrated with the SPIO prepa-
ration called Resovist/Ferucarbotran20. Other possibilities
will also be investigated for future work, including the use
of electroporation and protamine sulfate to introduce SPIO
into cells. Both of these methods have been shown to be
successful in the labelling of other cell types6,21e23.nate culture. As deﬁnitive evidence of the redifferentiation of dedif-
ied out. Approximately 40% of cell stained positively for collagen II
with SPIO (one-way ANOVA, n¼ 4). Perceived differences in col-
ution on the slides. As can be seen in Fig. 4(a) there was no overall
er of positive cells.
Fig. 5. Cell tracking in ex vivo cartilage defect model. MRI pictures of osteochondral plugs with a cartilage defect seeded with cells demon-
strates the ability to track as few as 10,000 labelled cells in a gel seeded in a cartilage defect created ex vivo. Labelled cells were detectable
surrounded by cartilage tissue at the periphery of the images. 10,000 Unlabelled cells served as control and were undetectable. The black
signal represents labelled cells surrounded by white cartilage.
966 E. Farrell et al.: Cell labelling with superparamagnetic iron oxideIn conclusion, this research found no effects of SPIO la-
belling of chondrocyte redifferentiation as evidenced by
gene and protein expression of common cartilage speciﬁc
markers and proteoglycan production. Iron particles were
retained intracellularly for 3 weeks apparently within dis-
crete compartments. This report illustrates the clinical po-
tential of such a labelling method in the treatment of joint
related injuries/diseases by cell therapy.Conﬂict of interest
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